The NHS will expand on existing efforts such as the 100,000 Genomes Project and will offer people with rare diseases the opportunity to sequence their genomes.
The £550,000 award is part of a larger multi-partner grant to develop and implement a point-of-care test to avoid antibiotic-related hearing loss in newborns.
Although a draft guidance last month recommended against use of molecular tests to guide chemotherapy, the group's finalized decision is subject to price negotiation and other adjustments.
An assessment concluded that Oncotype Dx has not demonstrated a significant enough impact on outcomes or cost effectiveness compared to current practice.
As of this week, the project had sequenced 39,500 genomes and returned reports for about 3,000 rare disease families and more than 600 cancer patients.
